RxDoctor Payments Data

Evan Fountain, MD

Pulmonary Disease · Brunswick, GANPI 1588046320

Payments from drug & device makers

$16,041in general payments, 2019–2025

Across 572 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$2K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Insmed, Inc.$971
  • Grifols USA, LLC$700
  • plus $7K from 43 others

What the payments were for

  • Travel & lodging$1851%
  • Food & beverage$12,67579%
  • Education$3,18120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,041 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$154,459
Medicare patients
592
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter286$252,860
Breztri AerosphereBudesonide/Glycopyr/Formoterol132$102,500
Fasenra PenBenralizumab12$67,930
TezspireTezepelumab-Ekko11$50,553
EliquisApixaban63$45,905
Stiolto RespimatTiotropium Br/Olodaterol Hcl73$44,590
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$27,096
Breo ElliptaFluticasone/Vilanterol24$13,107
SymbicortBudesonide/Formoterol Fumarate43$11,780
Spiriva RespimatTiotropium Bromide21$11,028
Combivent RespimatIpratropium/Albuterol Sulfate19$9,284
Wixela InhubFluticasone Propion/Salmeterol58$7,364
Albuterol Sulfate HfaAlbuterol Sulfate315$6,815
Varenicline Tartrate39$6,371
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$5,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,550$293,063371 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$1,511$164,833186 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$534$64,902113 claims
PfizerEliquis$90$45,90563 claims
MerckDulera$248$3,53712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →